FDA Approves Xalkori for Rare Genetic Form of Lung Cancer

Share this content:
FDA Approves Xalkori for Rare Genetic Form of Lung Cancer
FDA Approves Xalkori for Rare Genetic Form of Lung Cancer

FRIDAY, March 11, 2016 (HealthDay News) -- Xalkori (crizotinib) has been approved by the U.S. Food and Drug Administration to treat advanced non-small-cell lung cancer (NSCLC) with tumors that have a rare ROS1 gene mutation.

The drug was approved in 2011 to treat advanced NSCLC that was related to an abnormal ALK gene, the agency said Friday in a news release.

Clinical studies of 50 people with ROS1-positive NSCLC found that about two-thirds (66 percent) of participants treated with Xalkori had complete or partial shrinkage of tumors that lasted for a median of 18.3 months, the agency said.

The drug's most common side effects include nausea, diarrhea, vomiting, edema, constipation, elevated transaminases, fatigue, loss of appetite, and upper respiratory infection. More serious adverse reactions could include liver problems, lung inflammation, abnormal heartbeat, and loss of vision.

Xalkori is marketed by New York City-based Pfizer.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Actigraphy May Overestimate Sleep in ICU Setting

Actigraphy May Overestimate Sleep in ICU Setting

Wide ranges of sleep quality and quantity with use of actigraphy among critically ill patients in ICU

Mortality for Unintentional Drug Poisonings Up Since 1979

Mortality for Unintentional Drug Poisonings Up Since 1979

Trajectory of overall mortality rate smooth; no exponential trajectories in rates for individual drugs

Most Breast Cancer Diagnoses Given Over the Phone

Most Breast Cancer Diagnoses Given Over the Phone

This represents a reversal, with in-person diagnoses more common before 2006

is free, fast, and customized just for you!




Already a member?

Sign In Now »